Clinical trial
Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent…
NCT00006009 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00006009 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma |
| Official title | A Phase I, Multiple Dose Escalation Trial of Intravenous Humanized Anti-CD3 Antibody (HuM291) in Patients With CD3+ T-cell Lymphomas |
| Lead sponsor | Stanford University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Small Intestine Cancer |
| Intervention type | Biological |
| Interventions | visilizumab |
| Start date | Apr 1, 2001 |
| Completion | Oct 1, 2003 |
| First posted | Oct 8, 2003 |
| Last update posted | May 15, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: